article Open AccessTop 1% cited
Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial
Diabetologia · 2009 · Vol. 52(10) · pp. 2046–2055
on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group✉(Guildford Hospital)David Russell‐Jones(Steno Diabetes Centers)Allan Vaag(Aarhus University Hospital)O. Schmitz(CARE Hospitals)Bipin Sethi(University of Belgrade)Nebojša Lalić(University of Nis)Slobodan Antić(Novo Nordisk (Denmark))Marija Zdravković(Novo Nordisk (Denmark))Gabriela Martinez Ravn(Vall d'Hebron Institut de Recerca)Rafael Simó
Abstract
The study was funded by Novo Nordisk A/S.
Diabetes Treatment and ManagementDiabetes Management and ResearchPancreatic function and diabetesMedicineMetforminSulfonylureaLiraglutideInsulin glargineType 2 Diabetes MellitusPlaceboInternal medicineDiabetes mellitusExenatide
MeSH terms
Insulin GlargineLiraglutideAdolescentAdultAgedAged, 80 and overBlood GlucoseBody WeightDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleHumansHypoglycemic AgentsInsulinMale
Funding
- Novo Nordisk
Citations
827
FWCI
64.00
field-weighted impact
References
32
Percentile
100%
vs. same field & year
Citations per year
References
The Physiology of Glucagon-like Peptide 1
Physiological Reviews · 2007 · 3,192 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.